Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 356

1.

Composite T lymphoblastic leukemia/lymphoma and diffuse large B-cell lymphoma: case report.

Niino D, Ohsaki K, Arakawa F, Watanabe J, Kimura Y, Kiyasu J, Takeuchi M, Miyoshi H, Yoshida M, Sugita Y, Ohshima K, Okamura T.

Pathol Int. 2011 Jun;61(6):363-8. doi: 10.1111/j.1440-1827.2011.02662.x. Epub 2011 Mar 13.

PMID:
21615612
2.

Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.

Yamazaki S, Fujioka Y, Nakamura F, Ota S, Shinozaki A, Yamamoto G, Kamikubo Y, Nannya Y, Ichikawa M, Fukayama M, Kurokawa M.

Pathol Int. 2011 Nov;61(11):662-6. doi: 10.1111/j.1440-1827.2011.02713.x. Epub 2011 Aug 30.

PMID:
22029677
3.
4.

SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma.

Tomita N, Sakai R, Fujisawa S, Fujimaki K, Taguchi J, Hashimoto C, Ogawa K, Yamazaki E, Ishigatsubo Y.

Cancer Sci. 2012 Aug;103(8):1518-23. doi: 10.1111/j.1349-7006.2012.02331.x. Epub 2012 Jul 4.

5.

CD5+ T-cell/histiocyte-rich large B-cell lymphoma.

Chang CC, Bunyi-Teopengco E, Eshoa C, Chitambar CR, Kampalath B.

Mod Pathol. 2002 Oct;15(10):1051-7.

6.

EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.

Beltran BE, Castillo JJ, Morales D, de Mendoza FH, Quinones P, Miranda RN, Gallo A, Lopez-Ilasaca M, Butera JN, Sotomayor EM.

Am J Hematol. 2011 Aug;86(8):663-7. doi: 10.1002/ajh.22078.

8.

Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone.

Goto N, Tsurumi H, Takemura M, Kanemura N, Kasahara S, Hara T, Yasuda I, Shimizu M, Yamada T, Sawada M, Takahashi T, Yamada T, Seishima M, Moriwaki H, Takami T.

Leuk Lymphoma. 2012 Aug;53(8):1494-500. doi: 10.3109/10428194.2012.660627. Epub 2012 Mar 1.

PMID:
22280534
9.

Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.

Ozsan N, Cagirgan S, Saydam G, Gunes A, Hekimgil M.

Pathol Res Pract. 2013 Aug;209(8):471-8. doi: 10.1016/j.prp.2013.04.014. Epub 2013 May 9.

PMID:
23726928
10.

Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.

Tanaka T, Shimada K, Yamamoto K, Hirooka Y, Niwa Y, Sugiura I, Kitamura K, Kosugi H, Kinoshita T, Goto H, Nakamura S.

Ann Hematol. 2012 Mar;91(3):383-90. doi: 10.1007/s00277-011-1306-0. Epub 2011 Aug 6.

PMID:
21822617
11.

Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.

Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, Quek R, Tao M, Lim ST.

Ann Hematol. 2011 Jul;90(7):809-18. doi: 10.1007/s00277-010-1150-7. Epub 2011 Jan 13.

PMID:
21229246
12.

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.

Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.

Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.

PMID:
21874232
13.

CD5-positive follicular lymphoma: a case report and literature review.

Sekiguchi Y, Imai H, Wakabayashi M, Sawada T, Ichikawa K, Komatsu N, Noguchi M.

Intern Med. 2011;50(8):899-904. Epub 2011 Apr 15. Review.

14.

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C.

N Engl J Med. 2002 Jan 24;346(4):235-42.

15.

Lymphoblastic lymphoma.

Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D.

Crit Rev Oncol Hematol. 2011 Sep;79(3):330-43. doi: 10.1016/j.critrevonc.2010.12.003. Epub 2011 Jan 26. Review.

PMID:
21273093
16.

Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens.

Goto N, Tsurumi H, Kasahara S, Kanemura N, Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, Takemura M, Seishima M, Kito Y, Takami T, Moriwaki H.

Eur J Haematol. 2011 Sep;87(3):217-27. doi: 10.1111/j.1600-0609.2011.01649.x. Epub 2011 Jul 26.

PMID:
21575062
17.

The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R, Ott G, Rosenwald A, Braziel R, Campo E, Vose J, Lenz G, Staudt L, Chan W, Weisenburger DD.

Am J Clin Pathol. 2011 Jan;135(1):54-61. doi: 10.1309/AJCPJX4BJV9NLQHY.

PMID:
21173124
18.

[Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma].

Zhang HY, Guan ZZ, Wang B, Huang HQ, Xia ZJ, Lin TY.

Zhonghua Zhong Liu Za Zhi. 2008 May;30(5):381-4. Chinese.

PMID:
18953841
19.

Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.

Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM, Gascoyne RD.

J Clin Oncol. 2011 Apr 10;29(11):1452-7. doi: 10.1200/JCO.2010.33.3419. Epub 2011 Mar 7.

PMID:
21383296
20.

Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.

Koivula S, Valo E, Raunio A, Hautaniemi S, Leppä S.

Oncol Rep. 2011 Apr;25(4):1183-90. doi: 10.3892/or.2011.1179. Epub 2011 Feb 10.

PMID:
21318224

Supplemental Content

Support Center